Related Experiment Video

Updated: Jun 23, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Soluble tumor necrosis factor receptor 1 level is associated with left ventricular hypertrophy: the northern

Yasuyoshi Takei1, Marco R Di Tullio, Shunichi Homma

  • 1Division of Cardiology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, USA.

American Journal of Hypertension
|April 25, 2009
PubMed

Insights

Soluble tumor necrosis factor receptor 1 (sTNFR1) is linked to increased left ventricular mass, suggesting inflammation contributes to left ventricular hypertrophy (LVH). Other markers like hsCRP and IL-6 were not independently associated with LVH.

Area of Science:

  • Cardiology
  • Inflammation Research
  • Biomarkers

Background:

  • Inflammatory markers are linked to cardiovascular events.
  • Limited data exist on inflammatory markers and left ventricular hypertrophy (LVH).
  • This study investigates inflammatory markers and LVH in a multiethnic cohort.

Purpose of the Study:

  • To evaluate the independent association between inflammatory markers and LVH.
  • To assess the role of specific inflammatory markers in LVH development.

Main Methods:

  • Cross-sectional study of 660 participants without stroke.
  • Echocardiography performed for LV mass calculation.
  • Assessed soluble tumor necrosis factor receptor 1 (sTNFR1), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP).

Main Results:

  • Univariate analyses showed hsCRP, IL-6, and sTNFR1 associated with LV mass.
  • sTNFR1 remained independently associated with LV mass after adjustments.
  • hsCRP and IL-6 were not independently associated with LV mass in multivariate models.

Conclusions:

  • sTNFR1 is independently associated with increased LV mass.
  • Chronic subclinical inflammation, particularly the TNFR1 system, may contribute to LVH.
  • hsCRP and IL-6 are not independently associated with LVH in this population.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...